Holen Sie sich die Stockscreener-App
11.53
1.86%
0.21
Schlusskurs vom Vortag:
$11.32
Offen:
$11.41
24-Stunden-Volumen:
78,060
Relative Volume:
1.05
Marktkapitalisierung:
$243.55M
Einnahmen:
$217.21M
Nettoeinkommen (Verlust:
$-33.72M
KGV:
-7.1155
EPS:
-1.6204
Netto-Cashflow:
$25.63M
1W Leistung:
+0.00%
1M Leistung:
-15.41%
6M Leistung:
-23.03%
1J Leistung:
-41.29%
1-Tages-Spanne:
$11.32
$11.59
1-Wochen-Bereich:
$11.25
$11.85
52-Wochen-Spanne:
$11.25
$20.90
Amarin Corp Adr Stock (AMRN) Company Profile
Firmenname
Amarin Corp Adr
Sektor
Telefon
353 1 6699 020
Adresse
SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2
Compare AMRN vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRN
Amarin Corp Adr
|
11.53 | 243.55M | 217.21M | -33.72M | 25.63M | -1.6204 |
LLY
Lilly Eli Co
|
1,240.34 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
253.79 | 611.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
282.68 | 499.53B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
143.63 | 354.36B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
150.20 | 285.49B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amarin Corp Adr Stock (AMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-08-21 | Fortgesetzt | JP Morgan | Underweight |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-10-25 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-06 | Hochstufung | Jefferies | Hold → Buy |
| 2022-05-06 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-05 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-05-05 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-05-04 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2021-05-12 | Herabstufung | Goldman | Neutral → Sell |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-05 | Eingeleitet | Northland Capital | Outperform |
| 2020-03-31 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-31 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-31 | Hochstufung | Oppenheimer | Underperform → Perform |
| 2020-03-13 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-02 | Eingeleitet | Cowen | Outperform |
| 2020-02-18 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-01-06 | Eingeleitet | JP Morgan | Neutral |
| 2019-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2019-11-20 | Eingeleitet | Oppenheimer | Underperform |
| 2019-11-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-11-15 | Bestätigt | SVB Leerink | Outperform |
| 2019-10-31 | Eingeleitet | Aegis Capital | Buy |
| 2019-10-15 | Eingeleitet | Goldman | Neutral |
| 2019-08-14 | Eingeleitet | SVB Leerink | Outperform |
| 2019-07-09 | Bestätigt | Jefferies | Buy |
| 2019-06-17 | Eingeleitet | ROTH Capital | Buy |
| 2019-03-22 | Eingeleitet | Stifel | Buy |
Alle ansehen
Amarin Corp Adr Aktie (AMRN) Neueste Nachrichten
FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer - Zacks Investment Research
Here's Why You Should Add EYPT Stock to Your Portfolio Now - Zacks Investment Research
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week - Zacks Investment Research
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label - Zacks Investment Research
Here's Why You Should Add ANRO Stock to Your Portfolio Now - Zacks Investment Research
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal - Zacks Investment Research
BMY Reports Mixed Phase III Trial Results, Stock Down - Zacks Investment Research
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why - Zacks Investment Research
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know - Zacks Investment Research
argenx Meets Primary Endpoint in Phase II Celiac Disease Study - Zacks Investment Research
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia - Zacks Investment Research
Here's Why You Should Add LPCN Stock to Your Portfolio Now - Zacks Investment Research
ETON Stock Surges 108% in Six Months: Here's What You Need to Know - Zacks Investment Research
Amarin Corporation plc (AMRN) Options Chain - Yahoo! Finance Canada
Amarin Corporation plc (AMRN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study - Zacks Investment Research
Amarin Stock Price Forecast. Should You Buy AMRN? - StockInvest.us
Amarin Corporation plc (AMRN) Options ChainYahoo Finance - Yahoo! Finance Canada
Amarin Corporation plc (AMRN) Options ChainYahoo Finance - Yahoo! Finance Canada
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report? - Zacks Investment Research
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Amarin Highlights New ESC 2026 Data and Guideline Support Reinforcing Evidence for Icosapent Ethyl - Quiver Quantitative
Amarin analysis links Vascepa adherence to greater, longer-lasting heart benefits (AMRN:NASDAQ) - Seeking Alpha
Heart treatment linked to ~30% fewer major events; benefits may persist after stopping - Stock Titan
Amarin (NASDAQ: AMRN) sees Sarissa report 25.7M+ shares - Stock Titan
Amarin Announces REDUCE-IT-Related Presentations at ESC Congress 2026 in Munich - Quiver Quantitative
Five abstracts from an 8,179-patient study are set for the 2026 heart congress - Stock Titan
Amarin (AMRN) Holds Near $14.15 as Bulls Defend Key Support ZoneMomentum Stock Picks - careplusvn.com
Amarin Corporation Plc Sponsored ADR Revenue Breakdown – LSX:A41557 - TradingView
Earnings call transcript: Amarin Q2 2026 revenue falls, but cash flow improves - Investing.com
Amarin Corp PLC (AMRN) Q2 2026 Earnings Call Highlights: Strategic Growth Amidst Revenue Challenges - Yahoo Finance
Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short - TradingView
Amarin Corporation PLC reports results for the quarter ended June 30Earnings Summary - tradingview.com
Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short - Yahoo Finance
Amarin Corporation Plc Sponsored ADR Revenue Breakdown – FWB:EH3 - TradingView
Amarin Corporation PLC expected to post a loss of 1 cent a shareEarnings Preview - TradingView
Amarin CorpADR (AMRN) Fundamental & Financial Data - Stocktwits
AMRN: Amarin CorpADR Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Bears are Losing Control Over Amarin (AMRN), Here's Why It's a 'Buy' Now - Yahoo Finance
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma - TradingView
Amarin: The Market Is Pricing A 55% Chance Of A Sale That Isn't Coming (NASDAQ:AMRN) - Seeking Alpha
AMRNAmarin Corp ADR Options - Finviz
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why - TradingView
Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape - Barchart.com
Amarin Corporation Plc Sponsored ADR Actuals & Estimates (NASDAQ:AMRN) - TradingView
EH3 Forecast — Price Target — Prediction for 2027 - TradingView
EH3 Forecast — Price Target — Prediction for 2027 - TradingView
Here's Why You Should Add ANIX Stock to Your Portfolio Now - TradingView
Reasons Why Investors Should Consider Betting on Indivior Stock - TradingView
Net income before discontinued operations of Amarin Corporation Plc Sponsored ADR – DUS:EH3 - TradingView
Finanzdaten der Amarin Corp Adr-Aktie (AMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.79%
9.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):